Schonfeld Strategic Advisors LLC Takes Position in Emergent BioSolutions Inc. (NYSE:EBS)

Schonfeld Strategic Advisors LLC acquired a new stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 145,912 shares of the biopharmaceutical company's stock, valued at approximately $1,395,000. Schonfeld Strategic Advisors LLC owned about 0.27% of Emergent BioSolutions as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Covestor Ltd increased its stake in Emergent BioSolutions by 5,458.5% in the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 2,893 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Emergent BioSolutions during the fourth quarter valued at $63,000. E Fund Management Co. Ltd. purchased a new stake in Emergent BioSolutions during the fourth quarter valued at $98,000. Alpine Global Management LLC bought a new position in Emergent BioSolutions during the fourth quarter valued at $112,000. Finally, Cornercap Investment Counsel Inc. purchased a new position in shares of Emergent BioSolutions in the 4th quarter worth $115,000. Hedge funds and other institutional investors own 78.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday, April 1st. StockNews.com cut Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th.

Emergent BioSolutions Trading Up 1.1%

NYSE:EBS traded up $0.06 during mid-day trading on Monday, hitting $5.71. 323,374 shares of the stock traded hands, compared to its average volume of 1,902,336. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a 52 week low of $4.02 and a 52 week high of $15.10. The stock has a market capitalization of $310.37 million, a price-to-earnings ratio of -1.40 and a beta of 2.09. The firm's 50 day moving average is $5.14 and its two-hundred day moving average is $7.90.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating analysts' consensus estimates of $0.49 by $0.22. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The firm had revenue of $222.20 million for the quarter, compared to analysts' expectations of $218.50 million. On average, equities research analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Emergent BioSolutions declared that its board has initiated a share repurchase program on Monday, March 31st that permits the company to buyback $50.00 million in outstanding shares. This buyback authorization permits the biopharmaceutical company to reacquire up to 19% of its shares through open market purchases. Shares buyback programs are often a sign that the company's management believes its shares are undervalued.

Insider Activity

In related news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the transaction, the director now owns 101,100 shares of the company's stock, valued at $589,413. This represents a 25.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.20% of the company's stock.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.